Background: CYP2D6 plays a crucial role in drug metabolism of several drugs. It is known to be highly polymorphic with enzymatic activity ranging from poor to ultrarapid metabolic rates. While the frequencies of CYP2D6 alleles are generally known in different Asian populations, data on frequencies of the copy number variations (CNV) and tandems in CYP2D6 in which they occur are less well studied in these populations.
Methods:
A cohort of 800 consecutive, unrelated individuals were referred to Prenetics Limited (Prenetics) iGenes test by physicians in Hong Kong as part of their care with informed consent. These clinical samples were deidentified prior to further analysis. Genotyping and copy number determination of CYP2D6 were performed using target specific TaqMan ® SNP genotyping and copy number assays. The phenotypes of CYP2D6 were predicted based on its genotypes and is dependent on the biallelic expression of alleles.
Results: Among the Asian group (n = 735, 92%), the observed frequency of CYP2D6*36-*10 tandems was 34.1%. We also identified duplication of CYP2D6 alleles in 86 (11.7%) individuals of the study cohort. The frequency of all CYP2D6 duplicated alleles was 154 (10.5%) while only 28 (1.9%) of the duplications were of functional alleles (ie CYP2D6*1 and CYP2D6*2).
Conclusion:
The present study provides a comprehensive analysis on the occurrences of CNV and tandems of the CYP2D6 gene in the Hong Kong population. The results contribute to the overall knowledge of pharmacogenomics and may accelerate the implementation of precision medicine in Asia.
K E Y W O R D S
copy number variations, CYP2D6 genotyping, CYP2D6*36-*10, drug metabolism, tandem repeats altered CYP2D6 enzymatic activity both in vitro and in vivo. 7, 8 One such example is CYP2D6*36-*10 tandems, which is common in East Asian populations. 20, 21 The CYP2D6*36-*10 tandems convey activity only from CYP2D6*10 allele.
7,22
The frequency of CYP2D6 genetic polymorphisms varies significantly between different ethnic groups. While the frequencies of CYP2D6 alleles are generally known in Asians, distribution of the copy number variations (CNV) and tandems in CYP2D6 in which they occur are less well studied in these populations. 19 The objective of this study is to determine and report the observed CYP2D6 allele and predicted phenotype frequencies, specifically the occurrences of CNV and tandems, in the Hong Kong population. 
| ME THODS

| Study subjects
| Allelic ratios determination
For samples that carry CYP2D6 duplications and are heterozygous for key CYP2D6 variants, the allele-specific copy number is deter- F I G U R E 3 Functional status of copy number variants in the Asian group among the study cohort. A, Frequencies of alleles which include 2 or more copie of normal function genes (n = 28). B, Frequencies of alleles which include 2 or more copies of decreased function variants or tandems with decreased function (n = 61). xN denotes the presence of more than 3 copies of CYP2D6 allele. C, Frequencies of alleles which include gene deletions (CYP2D6*5) and 2 or more copies of variants with no function (n = 65). xN denotes the presence of more than 3 copies of CYP2D6 allele
| Phenotype prediction
The phenotypes of CYP2D6 were predicted using an activity scoring system described by Gaedigk et al 8 The CYP2D6 activity score is calculated by the summation of the activity value of each allele reported in the diplotype. Based on the activity score, the predicted phenotypes are determined based on CYP2D6 dosing guidelines as follow [12] [13] [14] [15] 22, 23 : activity score of 0 as poor metabolizer (ie, individual carrying two non-functional alleles); whereas activity score ranging from 1.5 to 2.0 as normal metabolizer (ie, individual carrying one functional allele and one decreased function alelle or two functional alleles); Predicted phenotype of intermediate metabolizer is more difficult to assess given the lack of consensus in regard to whether individual with a CYP2D6 activity score of 1.0 should be assigned an normal or intermediate phenotype (ie, individual carrying one functional allele and one non-functional allele or 2 decreased function alleles). 13, 15, 22, 23 Pharmacokinetic studies suggest such genotypes would confer decreased activity as compared to normal metabolizer, and could also be considered intermediate metabolizer. 24 Our group considered activity score ranging from 0.5 to 1.0 as intermediate metabolizer, which is consistent with the ACMG guidelines for tamoxifen 23 ; activity score greater than 2.0 as ultrarapid metabolizer (ie, individual carrying more than 2 copies of functional alleles).
| RE SULTS AND D ISCUSS I ON
| CYP2D6 alleles and phenotypes
The present study provides a comprehensive analysis on differ- . [25] [26] [27] [28] The frequencies of CYP2D6 alleles and predicted phenotypes among the Asian group in the study cohort are summarized in Tables 2 and 3 .
| CYP2D6*36-*10 tandems
As expected, CYP2D6*10 is one of the most commonly observed decreased-function alleles reported in Asians. This study reported an allele frequency of 21.6% in the study population which is much less than the observed frequencies of 60-70% reported previously. [25] [26] [27] [28] We suspected the major reason for these differ- 
| Copy number variations
The prevalence of duplicated CYP2D6 genes in Asians is poorly understood. 30 We identified multiplication of CYP2D6 alleles in 86 
| CON CLUS ION
